Sugi Predict

Sugi Predict / Compounds / SCHEMBL29358751

SCHEMBL29358751

SCHEMBL29358751

O=C1C=Cc2cccc3cc4ccccc4c1c23

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 3/20 0.51
▸ NQO1 P15559 2/20 0.46
▸ CYP1A2 P05177 3/20 0.42
▸ ACHE P22303 2/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ MAOA P21397 1/20 0.42
▸ AHR P35869 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ HIF1A Q16665 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6503129 1.00 CES1 (0.51) CES1NQO1CYP1A2ACHEERBB2
SCHEMBL6250997 0.78 CES1 (0.51) CES1NQO1CYP1A2ALDH1A1HPGD
SCHEMBL6250540 0.78 NQO1 (0.49) CES1NQO1CYP1A2ALDH1A1HPGD
SCHEMBL4977411 0.77 CES1 (0.43) CES1NQO1CYP1A2ACHEERBB2
SCHEMBL29562021 0.74 CYP1A2 (0.47) CES1NQO1CYP1A2ACHEERBB2
SCHEMBL26028 0.74 CYP1A2 (0.47) CES1NQO1CYP1A2ACHEERBB2
SCHEMBL21832124 0.74 CES1 (0.49) CES1NQO1CYP1A2ACHEERBB2
Triphenylene SCHEMBL22493025 0.73 CYP1A2 (0.46) CES1NQO1CYP1A2ACHEERBB2
SCHEMBL7741289 0.72 CES1 (0.38) CES1CYP1A2ACHEALDH1A1HPGD
SCHEMBL5716919 0.72 CES1 (0.79) CES1NQO1CYP1A2ACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024157278-A1 RAPID EXPRESSION AND SCREENING OF CELL PENETRATING PEPTIDES INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) 2024-08-02 — — WO claimed
EP-3507603-B1 COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE LIFE TECHNOLOGIES CORP (US) 2024-03-06 — — EP claimed
US-20230201380-A1 NON-INVASIVE AND LONGITUDINAL MONITORING OF MICROGLIAL ACTIVATION IN RAT BRAIN WITH SUPERMAGNETIC NANOPARTICLE ENHANCED MR IMAGING UNM RAINFOREST INNOVATIONS (US) 2023-06-29 — — US claimed
EP-4733317-A2 NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF MedImmune, LLC (US) 2026-04-29 — — EP disclosed
EP-3169407-B1 NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF MEDIMMUNE LLC (US) 2026-02-11 — — EP disclosed
US-12492240-B2 Neutralizing anti-influenza A antibodies and uses thereof MEDIMMUNE, LLC (US) 2025-12-09 — — US disclosed
US-12487180-B2 Device and methods for quantifying analytes introduction Life Technologies Corporation (US) 2025-12-02 — — US disclosed
US-20250333729-A1 TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF Life Technologies Corporation 2025-10-30 — — US disclosed
EP-4633458-A1 SYSTEMS AND METHODS FOR ANALYTE DETECTION Adaptyx Biosciences, Inc. (US) 2025-10-22 — — EP disclosed
US-20250302952-A1 METHOD OF TREATING INFLUENZA A MEDIMMUNE, LLC 2025-10-02 — — US disclosed
US-20250263470-A1 NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF MEDIMMUNE LLC (US) 2025-08-21 — — US disclosed
US-20220160882-A1 METHOD OF CONJUGATING A POLYPEPTIDE MEDIMMUNE, LLC 2022-05-26 — — US disclosed
US-20220112551-A1 OPTICALLY-BASED NANOPORE ANALYSIS WITH REDUCED BACKGROUND QUANTAPORE, INC. (US) 2022-04-14 — — US disclosed
US-20220098658-A1 METHODS TO MINIMIZE PHOTODAMAGE DURING NUCLEIC ACID AND PEPTIDE SEQUENCING Quantum-Si Incorporated (US) 2022-03-31 — — US disclosed
WO-2022061310-A1 METHODS TO MINIMIZE PHOTODAMAGE DURING NUCLEIC ACID AND PEPTIDE SEQUENCING Quantum-Si Incorporated (US) 2022-03-24 — — WO disclosed
EP-3438131-B1 OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS LIFE TECHNOLOGIES CORP (US) 2022-03-16 — — EP disclosed
US-20220072001-A1 G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2022-03-10 — — US disclosed
US-20220042915-A1 DEVICE AND METHODS FOR QUANTIFYING ANALYTES INTRODUCTION INVITROGEN CORPORATION 2022-02-10 — — US disclosed
US-20220033480-A1 NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF MEDIMMUNE LLC 2022-02-03 — — US disclosed
US-20220025020-A1 NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF MEDIMMUNE LLC 2022-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333729-A1 TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF RNGTT, RNMT, CPSF7 CES1 3021/4885NQO1 4390/4885CYP1A2 4877/4885
US-20220160882-A1 METHOD OF CONJUGATING A POLYPEPTIDE ZYX, QPCT, MRPL21 CES1 1749/4885NQO1 572/4885CYP1A2 3569/4885
US-20220072001-A1 G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES GCGR, GPR3, GPR132 CES1 4295/4885NQO1 4151/4885CYP1A2 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.